Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AdcendoAnnounceChange

More Like This

PR Newswire associated0

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

PR Newswire associated0

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

PR Newswire associated0

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

PR Newswire associated0

Prescient Healthcare Group Announces the Appointment of Two New Members to Its Board of Directors

Merck invests €70 million to triple its antibody-drug conjugate (ADC) manufacturing capacity and upgrade 3200 m2 at its BioConjugation Center of Excellence in St. Louis, Missouri, USA. (Photo: Business Wire)

Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies

Avance Clinical Announces Senior Appointment to North American Operations

Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data